iPS Academia Japan

What iPS Academia Japan does

iPS Academia Japan, Inc. (iPS アカデミアジャパン株式会社) is a Japanese technology licensing organization (TLO) founded on June 25, 2008 and headquartered on the Kyoto University (京都大学) Yoshida campus in Sakyo-ku, Kyoto. The company manages and licenses intellectual property derived from induced pluripotent stem cell (iPS cell) research, controlling licensing rights to more than 500 patent families that cover Yamanaka-factor reprogramming (Oct3/4, Sox2, Klf4, c-Myc), differentiation protocols for cardiomyocytes, hepatocytes, neurons, pancreatic beta cells, skeletal muscle, renal, germline, and hematopoietic cells, alongside purification technologies (mRNA switches, miRNA-responsive systems) and CRISPR-Cas-based genome editing. Following designation as an Approved TLO under Japan's University Technology Transfer Promotion Act on January 22, 2016, and a 2020 share acquisition in which Kyoto University purchased all voting stock, the company has operated as a wholly-owned subsidiary of the national university with Nobel laureate Shinya Yamanaka (山中 伸弥) as Scientific Advisor.

Revenue is generated exclusively through non-exclusive patent licensing under three programs: Internal Research Licenses (upfront and annual maintenance fees for preclinical use), Manufacturing/Sales/Service Licenses (upfront fees, running royalties, and minimums for commercial products and CRO services), and Medical/Therapeutic Use Licenses (upfront fees, IND/NDA-stage milestones, sales-tier milestones at US$100M and US$500M thresholds, 1.5% running royalties on product sales, and post-approval minimums). Pricing is bifurcated between venture companies (defined as within 10 years of founding, ≤50 employees, ≤US$20M in cumulative funding) and larger entities — venture therapeutic upfront fees are US$13,000 versus US$60,000 for non-ventures, with proportional differentials on maintenance, milestones, and minimums. The company serves more than 250 licensees globally, with named enterprise and biotech licensees including FUJIFILM Corporation, Takara Bio, HEALIOS K.K., BlueRock Therapeutics, Aspen Neuroscience, FUJIFILM Cellular Dynamics, Rege Nephro, Merck Sharp & Dohme Corp. (MSD), STEMCELL Technologies, and NACALAI TESQUE. Financial figures are not publicly disclosed.

Go-to-market is sales-led, executed via direct outreach and recurring participation in BioJapan, the BIO International Convention, BIO-Europe, ChinaBio, and the CiRA International Symposium, supplemented by multilingual web resources and an inbound Patent Introduction Service that continuously expands the licensed portfolio. The patent supply base comprises 15+ academic partners including Kyoto University, Osaka University, Gifu University, St. Marianna University School of Medicine, Tokyo Women's Medical University, Yokohama City University, Chiba University, and Singapore's A*STAR through Exploit Technologies. Licensees are distributed approximately Japan (125), North America (93), Europe (58), and Asia (12). The portfolio continues to be refreshed, with 30 patents added in December 2025 and a further 8 added in June 2026 covering pancreatic beta cells, mature cardiomyocytes, nerve cell maturation, cardiac function improvement, mesenchymal stem cells, and disease prognosis prediction. The company is privately held, employs between 1 and 10 people, and does not publicly disclose revenue.

Name

iPS Academia Japan

Legal name

iPS academiacia Japan株式会社

Website

https://ips-cell.net

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

iPS Academia Japan is a Kyoto-headquartered Approved Technology Licensing Organization and wholly-owned Kyoto University subsidiary that licenses 500+ iPS cell patent families to 250+ pharmaceutical, biotech, reagent, and research service companies worldwide.

Ownership category

akta.pro rank

Product category

Technology Transfer and Patent Licensing

NAICS

Scientific Research and Development Services (5417)

SIC

Patent Owners & Lessors (6794)

akta.pro primary industry

IP Licensing, Transactions & Technology Transfer (BPAHAMAF)

akta.pro secondary industries

IP Search, Watch & Competitive Intelligence (BPAHAMAI), IP Due Diligence & Freedom-to-Operate (FTO) Analysis (BPAHAMAG), IP & Patent Information Publishing (Patent/Litigation Analytics, Prior Art) (MPAJACAK)

Keywords

• Patent licensing services
• IPS cell technology
• Technology transfer organization
• Regenerative medicine licensing
• Stem cell patent portfolio

Headquarters

HQ city

Kyoto

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Patent Licensing - Internal Research: Non-exclusive license agreements for companies conducting internal research using iPS cells. Revenue generated through upfront fees, annual maintenance fees, and potential milestone payments based on research scope and territory.
2. Patent Licensing - Manufacturing/Sales/Service: Licenses for companies manufacturing and selling iPS cells, iPS cell-derived differentiated cells, iPS cell kits, and related services. Revenue includes upfront fees, running royalties on sales, and annual minimum royalties.
3. Patent Licensing - Therapeutic Use: Licenses for regenerative medicine and cell therapy applications using iPS cell-derived products. High-value licensing with upfront fees, annual maintenance fees, milestone payments at clinical trial stages (IND/NDA), and running royalties on product sales.
4. Patent Introduction Services: Managing patent portfolios from multiple academic institutions, evaluating and incorporating new patent applications into the licensing program.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

iPS Academia Japan is a government-approved Technology Licensing Organization (TLO) that manages and licenses the foundational intellectual property portfolio for induced pluripotent stem cell (iPS cell) technologies on behalf of Kyoto University and partner academic institutions. It sells non-exclusive patent licenses under three programs — Internal Research, Manufacturing/Sales/Service, and Medical/Therapeutic Use — to pharmaceutical, biotech, reagent, medical device and research service companies worldwide. It also operates a Patent Introduction Service that acquires new iPS cell inventions from academia and industry and adds them to the licensable portfolio.

Product overview

iPS Academia Japan is a patent licensing and technology transfer organization (TLO) that manages and commercializes iPS cell-related patents and technologies on behalf of Kyoto University and other research institutions. The company's core offerings consist of patent licensing programs categorized into Internal Research License (for basic research and preclinical studies), Manufacturing/Sales/Service License (for commercial products and services), and Medical/Therapeutic Use License (for regenerative medicine and cell therapy applications). Additionally, the company operates a Patent Introduction Service to expand its portfolio by acquiring relevant patents from academic and commercial sources. The Patent Portfolio encompasses over 60 patent families covering iPS cell reprogramming, differentiation methods for various cell types (cardiomyocytes, neurons, hepatocytes, pancreatic cells, skeletal muscle, kidney cells, hematopoietic cells), purification and cell selection technologies, genome editing, and applications in drug discovery and regenerative medicine. The company has established a licensee network of over 250 entities across pharmaceutical, biotechnology, reagent, research service, and medical device industries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Internal Research License Program Non-exclusive license program for companies conducting internal research, preclinical trials, and non-clinical studies using iPS cells and differentiated cells covered by the company's patents. Includes four contract types depending on whether the iPS cells are self-made or purchased and whether screening is involved; targeted at pharmaceutical R&D, biotech discovery, and academic-corporate research teams.
• Manufacturing, Sales & Service Provision License Non-exclusive license program for companies that manufacture and sell iPS cells, iPS-derived differentiated cells, iPS cell kits, or provide related services such as contract manufacturing, gene modification, pluripotency evaluation, and drug screening using iPS cells or differentiated cells. Pricing includes upfront fees, running royalties on sales, and annual minimum royalties.
• Medical/Therapeutic Use License License program for use of iPS cells in regenerative medicine, cell therapy, transplantation, and human/animal medical applications including treatment, prevention and diagnosis. Standardized financial terms include upfront fees, annual maintenance fees, IND and NDA milestone payments (for up to three regions), sales milestone payments at US$100M and US$500M, running royalty of 1.5% of sales, and annual minimum post-approval royalties; venture companies (within 10 years of founding, ≤50 employees, ≤US$20M funding) receive preferential rates.
• Patent Introduction Service Service for academic institutions, universities and companies that introduces iPS cell and pluripotent stem cell-related inventions into the iPS Academia Japan patent portfolio. Covers pre-grant applications through granted patents across diverse iPS cell fields and applications, enabling licensors to monetize inventions through the company's licensing program and Approved TLO infrastructure.

Quantifiable outcome

• Over 250 licensees globally, including major pharmaceutical companies, biotech firms, and research reagent manufacturers
• +1 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered flagship, secondary and core.

• Kyoto UniversityflagshipStrategic or Co-development Partner · 1 August 2020Kyoto University is the parent institution of iPS Academia Japan, having acquired all voting stocks in August 2020. The company manages the patent portfolio originally developed at Kyoto University, including inventions from Professor Shinya Yamanaka's laboratory. As a subsidiary, iPS Academia Japan operates as the primary technology transfer vehicle for iPS cell-related intellectual property from Kyoto University.
• Yokohama City UniversitysecondaryStrategic or Co-development Partner · 1 December 2019Collaborative agreement to support Yokohama City University's technology transfer activities in pluripotent stem cell research as an Accredited TLO.
• Chiba UniversitysecondaryStrategic or Co-development Partner · 1 August 2019Collaborative agreement to support Chiba University's intellectual property acquisition and technology transfer in pluripotent stem cell field.
• Kyoto University (additional license-in)coreTechnology or Integration · 1 June 201930 additional patent families licensed-in from Kyoto University, significantly expanding the portfolio.
• Kyoto University (additional license-in)coreTechnology or Integration · 1 May 201812 additional patent families licensed-in from Kyoto University.
• Tokyo Women's Medical University (TWMU)coreTechnology or Integration · 1 August 2017Exclusive license-in agreement for technology to reduce pluripotent stem cells in differentiated cell populations using temperature-based methods. Useful for preparing safe iPSC-derived differentiated cells for research and regenerative medicine.
• Osaka UniversitycoreTechnology or Integration · 1 August 2016Agreement for patent licensing-in from Osaka University, expanding the portfolio of available iPS cell-related technologies.
• Gifu UniversitysecondaryTechnology or Integration · 1 February 2016Collaborative agreement to support technology transfer and patent acquisition from Gifu University's pluripotent stem cell research.
• St. Marianna University School of MedicinesecondaryTechnology or Integration · 1 February 2016Agreement to support technology transfer and patent acquisition from St. Marianna University's research in pluripotent stem cells.
• Exploit Technologies Pte Ltd (ETPL), A*STARcoreTechnology or Integration · 1 September 2015License agreement for 3 families of patents relating to accelerated iPSC generation (AJ129, AJ130, AJ131). This international partnership expands the patent portfolio beyond Japanese academic institutions to include Singapore-based research.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Wisconsin Alumni Research Foundation (WARF): University-affiliated technology licensing organization that manages and licenses foundational research IP (notably CRISPR). Directly comparable to iPS Academia Japan as a non-profit/government-backed TLO commercializing academic inventions through structured licensing programs.
• Stanford Office of Technology Licensing (Stanford OTL): University TLO that licenses foundational life sciences IP originating from Stanford research. Same business model as iPS Academia Japan — multi-tiered licensing for research, commercial, and therapeutic use with milestone and royalty structures.
• Oxford University Innovation (OUI): UK university TLO that licenses life sciences and biotech IP from Oxford researchers. Operates the same patent licensing hub model with tiered licensing programs targeting pharmaceutical, biotech, and startup licensees.
• Max Planck Innovation: Technology transfer arm of the Max Planck Society that licenses life sciences and biotech IP from German academic institutions. Same operating model of aggregating university patent rights and licensing them to commercial entities in pharma and biotech.
• Cambridge Enterprise: Technology transfer company for the University of Cambridge that licenses biotech and life sciences IP. Comparable in mission and structure as a UK/EU university-linked TLO commercializing academic research.
• UniQuest (University of Queensland): Australia's leading university technology transfer company, commercializing life sciences IP including stem cell and regenerative medicine research. Same single-platform TLO model with milestone and royalty-bearing licensing programs.
• Cedars-Sinai Technology Ventures: Hospital/university-affiliated tech transfer unit licensing regenerative medicine and stem cell IP from Cedars-Sinai research. Operates similar licensing programs and competes for the same pharma/biotech licensee base.
• MRC Technology (LifeArc): UK medical research charity that licenses life sciences and therapeutic IP for translation into commercial products. Direct comparable as a non-profit tech transfer entity licensing therapeutic-stage research IP to pharma.

Regional players

• Japan Science and Technology Agency (JST): Japanese government agency that manages and licenses IP from publicly funded research, including some iPS-adjacent biotech IP. Domestic competitor in Japan for university tech transfer licensing business.

Broad incumbents

• IP Group plc: UK-listed IP commercialization company that forms and backs spinouts around university IP, particularly in life sciences. Broader in scope than iPS Academia Japan but operates adjacent to university tech transfer value chains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iPS Academia Japan